Alghamdi Adel, Alsaeddi Abeer, Malki Hashem, Alsaedi Ameerah
Diabetes and Endocrinology, Diabetes Center of Hera General Hospital, Makkah, SAU.
Family Medicine, Al-Awali Primary Health Care, Makkah, SAU.
Cureus. 2023 Sep 4;15(9):e44644. doi: 10.7759/cureus.44644. eCollection 2023 Sep.
Among women of childbearing age, type 2 diabetes mellitus (T2DM) is becoming more prevalent, increasing the likelihood of abortion, congenital anomalies, and neonatal death. Dulaglutide has not been adequately studied to determine if it causes birth defects or miscarriages during pregnancy. According to animal studies, the fetus is at risk from the use of dulaglutide during pregnancy. We report the case of a 39-year-old woman with T2DM who used dulaglutide (1.5 mg/week) along with glargine and aspart before conception. During the third month of pregnancy, she was seen in the clinic for the first time during which dulaglutide was stopped and basal-bolus insulin therapy was retained with dosing titration. The newborn was a male with a normal birth weight for his gestational age. Dulaglutide did not affect development. No minor or major malformations were noted in the fetus except for mild bilateral renal pyelectasis. Moreover, no maternal or fetal complications were observed. It is not possible to ascertain the safety of glucagon-like peptide-1 receptor agonists in pregnancy, despite the normal outcome in the present pregnancy; however, the data described here may be of value in further considering this issue.
在育龄女性中，2型糖尿病（T2DM）正变得越来越普遍，这增加了流产、先天性异常和新生儿死亡的可能性。度拉糖肽尚未得到充分研究以确定其在孕期是否会导致出生缺陷或流产。根据动物研究，孕期使用度拉糖肽会使胎儿面临风险。我们报告了一例39岁的T2DM女性病例，她在受孕前使用度拉糖肽（1.5毫克/周）联合甘精胰岛素和门冬胰岛素。在怀孕第三个月时，她首次到诊所就诊，此时停用了度拉糖肽，继续采用基础-餐时胰岛素治疗并调整剂量。新生儿为男性，出生体重与其孕周相符。度拉糖肽未影响发育。除轻度双侧肾盂积水外，未发现胎儿有轻微或严重畸形。此外，未观察到母体或胎儿并发症。尽管本次妊娠结局正常，但仍无法确定胰高血糖素样肽-1受体激动剂在孕期的安全性；然而，此处描述的数据可能对进一步考虑该问题具有价值。
